Publisher： Bentham Science Publishers
E-ISSN： 2212-3954|3|1|34-39
ISSN： 1574-8898
Source： Recent Patents on CNS Drug Discovery, Vol.3, Iss.1, 2008-01, pp. : 34-39
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Multiple sclerosis (MS) is a demyelinating disease in which myelin autoreactive T cells drive a chronic inflammatory process leading to myelin destruction. A sexual dimorphism has been described, with prevalence in females and a better clinical course during pregnancy.Specific receptors have been identified for sex steroids in the cytoplasm of immune and neural cells.Experimental autoimmune encephalomyelitis (EAE), the most frequently studied animal model for MS, showed sex differences in the disease course and improvement by the use of exogenous sex steroids.The recent pilot studies in vivo also reported an improvement of MS by the administration of gonadal hormones (replacement therapy, testosterone, estriol) in the short time. A patent proposed estriol therapy to treat autoimmune related disorders (including MS). A clinical European trial is ongoing on the use of nomegestrol/estradiol in the post-partum period in order to prevent the relapses. Integrated therapies appear to be effective in both male and female MS patients.
Related content
Access to resources
Recommend
The use of valproic acid and multiple sclerosis
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 24, Iss. 3, 2015-03 ,pp. :
JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 14, Iss. 6, 1966-06 ,pp. :